Humacyte (HUMA) Non Operating Interest Expenses (2020 - 2026)

Humacyte (HUMA) has reported Non Operating Interest Expenses for 7 consecutive years, with $2.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Non Operating Interest Expenses fell 8.8% year-over-year to $2.3 million in Q2 2026; TTM through Jun 2026 was $10.3 million, a 1.85% decrease from a year earlier, with the FY2025 full-year figure at $11.2 million, up 21.27% from the prior year.
• Non Operating Interest Expenses was $2.3 million for Q2 2026 at Humacyte, up from $2.3 million in the prior quarter.
• Over five years, Non Operating Interest Expenses peaked at $3.1 million in Q4 2025 and troughed at $1.4 million in Q1 2022.
• A 5-year average of $2.1 million and a median of $2.0 million in 2024 frame the typical range for Non Operating Interest Expenses.
• Across the five-year window, Non Operating Interest Expenses surged 168.67% in 2022 and decreased 24.3% in 2026, its largest moves.
• Over 5 years, Non Operating Interest Expenses stood at $1.6 million in 2022, then advanced by 5.37% to $1.7 million in 2023, then surged by 45.22% to $2.5 million in 2024, then advanced by 23.33% to $3.1 million in 2025, then fell by 24.96% to $2.3 million in 2026.
• The last three Non Operating Interest Expenses figures came in at $2.3 million (Q2 2026), $2.3 million (Q1 2026), and $3.1 million (Q4 2025), per Business Quant data.